US to rule on research patent
astrobiologists at the meeting applauded the news, but vowed to keep lobbying for more money. "We can see this as the beginning of a negotiation," says Baruch Blumberg, a Nobel laureate and former director of the NASA Astrobiology Institute.
■

Tony Reichhardt
some success in related experiments with human cells. Francisco Silva is vice-president of research at PrimeGen Biotech, based in Irvine, California. He says that, working with samples from 22 testes, the company "has successfully therapeutically reprogrammed human germ cells and differentiated them to multiple cell types in vitro". Silva has presented the data at scientific meetings, and says he plans to submit results for publication soon. But Shinohara is again sceptical.
Hasenfuss, Shinohara and PrimeGen all say they have filed for international patents on their technologies. Some legal squabbles are likely. Hasenfuss, for example, claims work in adult mice is different from that in neonatal mice. Shinohara says the two experiments are essentially the same.
Whether any of the mouse-based claims would cover humans is not clear. Even if a patent office grants a patent, it may be invalidated by the courts, says Lynn Pasahow, an intellectual-property attorney with Fenwick & West in Mountain View, California (see 'US to rule on research patent'). "It may be difficult to know the scope of the valid claims, " he says.
In any case, researchers still have to show that the cells can be derived, grown and manipulated just like those from the alternative source, cloned embryos. In theory, the reprogrammable testes cells could circumvent the ethical difficulties of stemcell work that involves destroying human embryos. "This could put the embryonic stem-cell people out of business, " says Peter Donovan, a stem-cell expert at the University of California, Irvine. "But it remains to be seen whether they work in humans. " ■
David Cyranoski
NASA's Dawn asteroid mission has been revived. 
